Drug General Information
Drug ID	D04AMD
Former ID	DIB013123
Drug Name	ZD-6126
Drug Type	Small molecular drug
Indication	Cancer [ICD9: 140-229; ICD10:C00-C96]		Phase 2	[521567]
Company	Angiogene Pharmaceuticals Ltd; Angiogene
Structure		Download 2D MOL 3D MOL
Formula	C20H24NO8P
CAS Number	CAS 219923-05-4
PubChem Compound ID	9896434
Target and Pathway
Target(s)	Tubulin beta	Target Info	Inhibitor	[529270]
KEGG Pathway	Phagosome
	Gap junction
	Pathogenic Escherichia coli infection
NetPath Pathway	FSH Signaling Pathway
	TCR Signaling Pathway
	EGFR1 Signaling Pathway
PANTHER Pathway	Cytoskeletal regulation by Rho GTPase
	Huntington disease
Reactome	Regulation of PLK1 Activity at G2/M Transition
	Loss of Nlp from mitotic centrosomes
	Recruitment of mitotic centrosome proteins and complexes
	Loss of proteins required for interphase microtubule organization?from the centrosome
	Anchoring of the basal body to the plasma membrane
WikiPathways	Parkin-Ubiquitin Proteasomal System pathway
	Pathogenic Escherichia coli infection
	Mitotic G2-G2/M phases
References
Ref 521567	ClinicalTrials.gov (NCT00065572) Exploratory Study to Assess the Biological Activity of ZD6126 in Subjects With Newly Diagnosed Metastatic Renal Cell Carcinoma (Stage IV). U.S. National Institutes ofHealth.
Ref 529270	Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors. Invest New Drugs. 2008 Apr;26(2):159-67.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.